Did A Special Protocol Assessment Actually Hurt Debiovision’s Sanvar?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Gastrointestinal Drugs Advisory Committee concludes that flaws in the trial designed with FDA made it impossible to determine the efficacy of the drug for acute bleeding resulting from portal hypertension.
You may also be interested in...
Good Trials Built On Sturdy Protocols, Not Just SPA Agreements With FDA
A Special Protocol Assessment is no guarantee of FDA approval, or even a smooth development path
Good Trials Built On Sturdy Protocols, Not Just SPA Agreements With FDA
A Special Protocol Assessment is no guarantee of FDA approval, or even a smooth development path
Debiovision’s Sanvar Will Be Tough Sell To Advisory Panel
FDA has declared any positive results from a study of vapreotide to be statistically insignificant, immeasurably biased and possibly due to the endoscopic therapy rather than the drug.